Effect of disease duration in a randomized phase iii trial of rintatolimod, an immune modulator for myalgic encephalomyelitis/chronic fatigue syndrome

HIGHLIGHTS

• who: David R. Strayer et al. from the AIM ImmunoTech Inc, Philadelphia, Pennsylvania, United States of America, Vanderbilt University have published the article: Effect of disease duration in a randomized Phase III trial of rintatolimod, an immune modulator for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, in the Journal: PLOS ONE of August/26,/2020
• what: The ME/CFS patients enrolled into this trial had severe debilitation, with a median KPS of 50 (S2 Table), indicating a requirement for considerable daily assistance to care for their daily activities (S2 Table).
• how: Because the median duration . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.